

SPECIFICATION

TITLE OF THE INVENTION

ANALYSIS OF AGONIST-ACTIVITY AND ANTAGONIST-ACTIVITY TO CYTOKININ RECEPTOR

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates to a method for analyzing agonist-activity and antagonist-activity of an examinee to cytokinin receptor.

DESCRIPTION OF THE RELATED ART

Cytokinins are plant hormones relevant to cell division and differentiation of higher plants and are well-known as very important physiologically active substances having functions of inducing division of cells of higher plants, differentiating the callus and pith to the stems and leaves, ethiolating and defoliating leaves, preventing the falling of fruit, breaking the dominance of the terminal bud and the like [Cytokinins: Chemistry, Activity, and Function, CRC press (1994)]. The substances having cytokinins-like activities are usable as plant growth regulators, for example, fruit-falling preventive agents for fruits such as apple, orange, and the like, plant-falling preventive agents for rice plants, barley, wheat and the like by regulating the height of the plants, and sweetness increasing agents for fruits after harvest.

As a method for finding substances having such cytokinins-like

activities, conventionally employed is a method for observing and evaluating the physiological changes by directly spraying examinee substances to plant.

The aforementioned method has problems that it requires to prepare the examinee substances in amounts sufficient to directly spray them to plant and also requires immensely long time to observe and evaluate the growth of the plant and the physiological changes of the plant after spraying of the examinee substances. Therefore, it has been required for a long to develop a variety of methods for quickly finding substances having cytokinins-like activities with small amounts of examinee substances.

SUMMARY OF THE INVENTION

Inventors of the present invention have intensively investigated in such situations and first found protein functioning as a cytokinin receptor and subsequently found it possible to analyze the agonist-activity and the antagonist-activity of examinee substances to a cytokinin receptor by using the cytokinin receptor (“the analysis method”) and also it possible to quickly search substances having cytokinins-like activities even in a small amount of examinee substances by employing the analysis method and consequently reached the present invention.

The present invention provides:

1: A method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal

200 199 198 197 196 195 194 193 192 191 190 189 188 187 186 185 184 183 182 181 180 179 178 177 176 175 174 173 172 171 170 169 168 167 166 165 164 163 162 161 160 159 158 157 156 155 154 153 152 151 150 149 148 147 146 145 144 143 142 141 140 139 138 137 136 135 134 133 132 131 130 129 128 127 126 125 124 123 122 121 120 119 118 117 116 115 114 113 112 111 110 109 108 107 106 105 104 103 102 101 100 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 82 81 80 79 78 77 76 75 74 73 72 71 70 69 68 67 66 65 64 63 62 61 60 59 58 57 56 55 54 53 52 51 50 49 48 47 46 45 44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

transduction from the cytokinin receptor expressed in the transformed cell.

2: The method according to the above 1, wherein the transformed cell is a cell having a function of directly controlling the cell growth by intracellular signal transduction from the cytokinin receptor and the measurement of the existence or the quantity of the intracellular signal transduction is carried out using the quantity of the cell growth of the transformed cell as an indicator.

3: The method according to the above 1, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin receptor into a host cell so improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell.

4: The method according to the above 1, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin receptor into a host cell so improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell by deleting one or more of histidine kinase.

5: The method according to the above 1, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin receptor into a host cell having no cytokinin receptor.

6: The method according to the above 1, wherein the transformed cell is yeast.

7: The method according to the above 1, wherein the transformed cell is budding yeast.

8: The method according to the above 1, wherein the DNA coding the cytokinin receptor is any one of DNA coding the cytokinin receptor selected

from:

- (a) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 6;
 - (b) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 2;
 - (c) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 4;
 - (d) a cytokinin receptor wherein said cytokinin receptor has at least one transmembrane region but less than that in its natural form.
 - (e) a cytokinin receptor having the amino acid sequence from amino acid number 196 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
 - (f) a cytokinin receptor having the amino acid sequence from amino acid number 50 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
 - (g) a cytokinin receptor having the amino acid sequence from amino acid number 32 to 1036 among the amino acid sequence represented by SEQ ID No: 4;
 - (h) a chimera-type cytokinin receptor comprising extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, and histidine kinase regions of the cytokinin receptor, wherein each of the regions is a homogeneous region to one another and receiver regions for the histidine kinase, which are heterogeneous regions to these regions; and
 - (i) a cytokinin receptor having the amino acid sequence with deletion, substitution, or addition of one or a plurality of amino acids in the amino

acid sequence of the cytokinin receptor of (a), (b), (c), (e), (f), or (g).

9: A method for analyzing antagonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and
(2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell.

10: The method according to the above 9, wherein the transformed cell is a cell having a function of directly controlling the cell growth by intracellular signal transduction from the cytokinin receptor and the measurement of the existence or the quantity of the intracellular signal transduction is carried out using the quantity of the cell growth of the transformed cell as an indicator.

11: The method according to the above 9, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin receptor into a host cell so improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell.

12: The method according to the above 9, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin receptor into a host cell so improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell by deleting one or more of histidine kinase.

13: The method according to the above 9, wherein the transformed cell is a transformed cell generated by introducing DNA coding the cytokinin

receptor into a host cell having no cytokinin receptor.

14: The method according to the above 9, wherein the transformed cell is yeast.

15: The method according to the above 9, wherein the transformed cell is budding yeast.

16: The method according to the above 9, wherein the DNA coding the cytokinin receptor is any one of DNA coding the cytokinin receptor selected from:

- (a) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 6;
- (b) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 2;
- (c) a cytokinin receptor having the amino acid sequence represented by SEQ ID No: 4;
- (d) a cytokinin receptor wherein said cytokinin receptor has at least one transmembrane region but less than that in its natural form.
- (e) a cytokinin receptor having the amino acid sequence from amino acid number 196 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
- (f) a cytokinin receptor having the amino acid sequence from amino acid number 50 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
- (g) a cytokinin receptor having the amino acid sequence from amino acid number 32 to 1036 among the amino acid sequence represented by SEQ ID No: 4;

- (h) a chimera-type cytokinin receptor comprising extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, and histidine kinase regions of the cytokinin receptor, wherein each of the regions is a homogeneous region to one another and receiver regions for the histidine kinase, which are heterogeneous regions to these regions; and
- (i) a cytokinin receptor having the amino acid sequence with deletion, substitution, or addition of one or a plurality of amino acids in the amino acid sequence of the cytokinin receptor of (a), (b), (c), (e), (f), or (g).

17: A cytokinin receptor selected from:

- (d) a cytokinin receptor wherein said cytokinin receptor has at least one transmembrane region but less than that in its natural form.
- (e) a cytokinin receptor having the amino acid sequence from amino acid number 196 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
- (f) a cytokinin receptor having the amino acid sequence from amino acid number 50 to 1176 among the amino acid sequence represented by SEQ ID No: 2;
- (g) a cytokinin receptor having the amino acid sequence from amino acid number 32 to 1036 among the amino acid sequence represented by SEQID No: 4;
- (h) a chimera-type cytokinin receptor comprising extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, and histidine kinase regions of the cytokinin receptor, wherein each of the regions is a homogeneous region to one another and receiver regions for the histidine kinase, which are heterogeneous regions to these regions; and

5 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0

(i) a cytokinin receptor having the amino acid sequence with deletion, substitution, or addition of one or a plurality of amino acids in the amino acid sequence of the cytokinin receptor of (e), (f), or (g).

18: DNA coding the cytokinin receptor of the above 17.

19: A transformed cell into which DNA of the above 18 is introduced.

20: A method for detecting agonist-activity to a cytokinin receptor, which comprises evaluating the agonist-activity of two or more different examinee substances to the cytokinin receptor based on the difference obtained by comparison of the existence or the quantity of the intracellular signal transduction in a section where the examinee substances are independently used and measured by the analysis method of the above 1.

21: The method according to the above 20, wherein at least one substance among the two or more different examinee substances is a substance having no agonist-activity to the cytokinin receptor.

22: A method for searching agonist-active substance to a cytokinin receptor, which comprises selecting a substance having agonist-activity to a cytokinin receptor based on the agonist-activity to a cytokinin receptor evaluated by the detecting method of the above 20.

23: A plant growth regulator comprising the substances selected by the searching method of the above 22 as an active ingredient.

24: A method for detecting antagonist-activity to a cytokinin receptor, which comprises evaluating the antagonist-activity of two or more different examinee substances to the cytokinin receptor based on the difference obtained by comparison of the existence or the quantity of the intracellular signal transduction in a section where the examinee

substances are independently used and measured by the analysis method of the above 9.

25: The method according to the above 24, wherein at least one substance among the two or more different examinee substances is a substance having no antagonist-activity to the cytokinin receptor.

26: A method for searching antagonist-active substance to a cytokinin receptor, which comprises selecting a substance having antagonist-activity to a cytokinin receptor based on the antagonist-activity to a cytokinin receptor evaluated by the detecting method of the above 24.

27: A plant growth regulator comprising the substances selected by the searching method of the above 26 as an active ingredient.

Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20256464 20256464 20256464 20256464 20256464

Hereinafter, the present invention will be described in detail.

A cytokinin receptor is protein having functions of controlling the propagation and differentiation of cells of higher plants based on the intracellular signal transduction mechanism so-called Two-Component regulatory system (or Histidine to Aspartic acidartic acid phosphorelay system) while being specifically bonded with cytokinins such as purine type cytokinins, e.g. kinetin, zeatin, and the like, and urea type cytokinins, e.g. N-phenyl-N'-(4-pyridyl)urea and the like. The cytokinin receptor to be used in the present invention belongs to the histidine kinase family and is protein composed of extracellular regions, transmembrane regions, histidine kinase regions (regions having histidine kinase activity in the cell and holding Histidine residue to be an active site), and receiver regions (regions having a reception part for phosphate group transfer and holding Aspartic acid residue to be an active site).

Practical examples of the cytokinin receptor are cytokinin receptors having the amino acid sequences represented by SEQ ID Nos: 2, 4, and 6, cytokinin receptors having the amino acid sequences represented by SEQ ID Nos: 2, 4, and 6 wherein one or a plurality of amino acids are deleted, substituted, or added, cytokinin receptors having the amino acid sequences coded with DNA to be hybridized in stringent conditions with DNA having the nucleotide sequences coding the amino acid sequences represented by SEQ ID Nos: 2, 4, and 6, cytokinin receptors of partially transmembrane region-deleted type which will be described later, and chimera-type cytokinin receptors which will be described later, and the like. Incidentally, the phrase, "a plurality of amino acids", means more particularly about 2 to

PCT/EP2015/062003

20 amino acids and for example, 2 to 10 amino acids and 2 to 5 amino acids may be exemplified. Also, the phrase, "the amino acid sequences ... wherein one or a plurality of amino acids are deleted, substituted, or added", means as examples those having the amino acid sequences of which 80% or higher, preferably 90% or higher, and more preferably 95% or higher are identical with the sequences of the amino acids before the deletion, substitution or addition of amino acids (i.e. amino acid sequence identification of 80% or higher, particularly 90% or higher, and more preferably 95% or higher).

Those phrases, "deletion, substitution or addition of amino acids" or "which 80% or higher ... are identical" of course include the intracellular processing to which proteins having the amino acid sequences represented by SEQ ID Nos: 2, 4, and 6 are subjected, and the natural variations caused by differences in type of organisms from which the proteins are derived, differences in individual bodies, differences in tissues, and the like.

The phrase, "sequence identification", in the present invention means the identification and homology between two DNA sequences and between two protein sequences. The sequence identification may be determined by comparing two sequences aligned in the optimum states in a region of the sequences of the comparison objects. The DNA or proteins, the comparison objects, may have addition or deletion (e.g. gap and the like) in the optimum alignment of two sequences. Regarding such sequence identification, computation may be performed using, for example, Vector NTI by producing alignment by utilizing Clusta 1W algorithm [Nucleic Acid Res., 22 (22): 4673-4680 (1994)]. Incidentally, the sequence identification

may be measured by a sequence analysis soft, practically Vector NTI, GENETYX-MAC and analysis tools provided in public database. The aforementioned public database may be, in general, accessible in, for example, home address: <http://www.ddbj.nig.ac.jp>.

Regarding the phrase, "be hybridized in stringent conditions", the term, hybridization, in this case may be performed, for example, according to a common method described in Molecular Cloning 2nd edition, written by Sambrook J., Frisch E. F., Maniatis T., issued by Cold Spring Harbor Laboratory press. Further, the phrase, "in stringent conditions", means, for example, that a hybrid is formed in a solution of $6 \times$ SSC (a solution containing 1.5 M NaCl and 0.15 M trisodium citrate is defined as $10 \times$ SSC) at 65 °C and then washed with $1 \times$ SSC at a room temperature. The salt concentration in the washing step may be selected, for example, from the condition of $1 \times$ SSC at a room temperature (a low stringent condition) to $0.1 \times$ SSC at a room temperature (a high stringent condition). The temperature in the washing step may be selected, for example, from a room temperature (a low stringent condition) to 68°C (a high stringent condition). Further, both of the salt concentration and the temperature may be changed.

(Production of a transformed cell into which DNA coding a cytokinin receptor is introduced)

A transformed cell into which DNA coding a cytokinin receptor is introduced may be obtained by introducing and expressing DNA coding the cytokinin receptor, that is, DNA having nucleotide sequence coding the amino acid sequence of the cytokinin receptor in a host cell in the following

manner. Hereinafter, one example of the method of the production of a transformed cell will be described.

(1) Preparation of cDNA

At first, the total RNA is prepared from plants such as higher plants according to the method described in Molecular Cloning 2nd edition written by J., Sambrook, E., F., Frishch, T., Maniastis.

Concretely, for example, after a part of tissues are sampled from a higher plant such as a monocotyledonous plant, e.g. rice, corn, barley, wheat and the like and a dicotyledonous plant, e.g. tobacco, soybean, Arabidopsis, and the like and then the tissues are frozen in liquefied nitrogen and successively physically milled using a mortar and pestle or the like and after that, either (a) the resulting milled product is mixed with a solution containing guanidine hydrochloride with phenol or SDS with phenol to obtain the total RNA or (b) the resulting milled product is mixed with a solution containing guanidine thiocyanate and further with CsCl and then subjected to centrifugal separation to obtain the total RNA. For the aforementioned process, commercialized kits such as ISOGEN (produced by Nippon Gene Co.), RNeasy Total RNA Purification Kit (produced by QIAGEN Co.), and the like may be employed.

Next, mRNA is prepared from the total RNA. For example, the preparation may be carried out by a method utilizing the hybridization of oligo-dT chains bonded with cellulose or latex and poly-A chains of mRNA. For the operation, for example, commercialized kits such as mRNA Purification Kit (produced by Amersham Pharmacia Co.), Oligotex TM-dT30 (super) (produced by Takara Shuzo Co. Ltd.), and the like may be employed.

Further, cDNA is produced using the mRNA (mRNA having poly-A chains) prepared in such a manner. For example, oligo-dT chains or random primers are annealed with mRNA and then reacted with reverse transcriptase to produce cDNA. Further, the cDNA is reacted with, for example, RNaseH, DNA polymerase I to produce double chain cDNA. For the operation, for example, the following commercialized kits may be employed: SMARTTM PCR cDNA Synthesis Kit (produced by Clontech Co.), cDNA Synthesis Kit (produced by Takara Shuzo Co. Ltd.), cDNA Synthesis Kit (produced by Amersham Pharmacia Co.), ZAP-cDNA Synthesis Kit (produced by Stratagene Co.) and the like.

(2) Cloning

The DNA coding the cytokinin receptor may be obtained by a polymerase chain reaction (hereinafter referred as to PCR) from the produced cDNA using, for example, DNA having partial nucleotide sequence of the nucleotide sequence of SEQ ID No: 1, 3 or 5 as a primer or by a hybridization method using DNA having partial nucleotide sequence of the nucleotide sequence of SEQ ID No: 1, 3 or 5 as a probe.

In the case of employing PCR, DNA usable as a primer set is those planned and synthesized based on the nucleotide sequences of about 20 bp to 40 bp, for example, the nucleotide sequences selected respectively from 5'-non-translation regions and 3'-non-translation regions of the nucleotide sequence represented by SEQ ID No: 1, 3, or 5. Examples of the primer set are sets of DNA of nucleotide sequence represented by SEQ ID No: 9 and DNA of nucleotide sequence represented by SEQ ID No: 10. The PCR solution to be used may be prepared by adding reaction solutions instructed

DRAFT
2023/03/28

by the kit to cDNA 250 ng. The conditions of the PCR may properly be changed depending on the primer set to be used and, for example, concrete conditions include as follows: keeping at 94°C for 2 minutes, at about 8°C for 3 minutes, and further repeating 40 cycles each of which comprises steps of keeping at 94°C for 30 seconds, at 55 °C for 30 seconds, and at 72°C for 4 minutes; and repeating 5 to 10 cycles each of which comprises steps of keeping at 94°C for 5 seconds and at 72°C for 4 minutes and further repeating about 20 to 40 cycles each of which comprises steps of keeping at 94°C for 5 seconds and at 70°C for 4 minutes. For the operation, the following commercialized kits may be, for example, employed: Takara Heraculase™ (produced by Takara Shuzo Co., Ltd.), DNA polymerase contained in Advantage cDNA PCR Kit (Clontech Co.), TAKARA Ex Taq (Takara Shuzo Co., Ltd.), PLATINUMTM PCR SUPER Mix (Lifetech Oriental Co.), and the like.

In the case of employing hybridization, cloning may be carried out according to a method described in, for example, "Cloning and Sequence", Experimental Manual of Plant Biotechnology (edited by Watanabe and Sugiura, Noson Bunka Publisher, 1989)

The probe to be used may be obtained by synthesizing DNA (with the chain length of about 200 nucleotides to 500 nucleotides) having partial nucleotide sequences of the nucleotide sequence represented by SEQ ID No: 1, 3 or 5 and labelling the DNA with radioisotope markers or fluorescent markers according to the known methods using, for example, Random Primed DNA Labelling Kit (Boehringer Co.), Random Primer DNA Labelling Kit Ver. 2 (Takara Shuzo Co., Ltd.), ECL Direct Nucleic Acid

Labelling and Detection System (Amersham Pharmacia Co.), Megaprime DNA-labelling system (Amersham Pharmacia Co.) and the like.

Examples of the hybridization conditions include stringent conditions and the following conditions may be exemplified: keeping at 65°C in the presence of 6 × SSC (0.9 M NaCl and 0.09 M trisodium citrate), 5 × Denhard's solution [0.1% (w/v) ficoll 400, 0.1% (w/v) polyvinylpyrrolidone, 0.1% BSA], 0.5% (w/v) SDS and 100 μg/ml degenerated salmon sperm DNA or in DIG EASY Hyb solution (Boeringer-Mannheim Co.) containing 100 μg/ml of degenerated salmon sperm DNA, successively keeping at a room temperature for 15 minutes two times in the presence of 1 × SSC (0.15 M NaCl and 0.015 M trisodium citrate) and 0.5% (w/v) SDS, and further keeping at 68°C for 30 minutes in the presence of 0.1 × SSC (0.015 M NaCl and 0.0015 M trisodium citrate) and 0.5% SDS.

In order to obtain DNA coding the cytokinin receptor of *Arabidopsis*, PCR is carried out employing TAKARA LA taqTM (Takara Shuzo Co., Ltd.) and using a solution containing cDNA library phage of *Arabidopsis* (about 1,000,000 pfu) as a template and DNA having the nucleotide sequence represented by SEQ ID No: 11 and DNA having the nucleotide sequence represented by SEQ ID No: 12 as a primer set to amplify and obtain DNA to be a probe. The PCR solution to be used may be prepared by adding the reaction solutions instructed by the kit to 250 ng of cDNA library.

The PCR conditions may be as follows: keeping at 94 °C for 2 minutes, at 8 °C for 3 minutes, and further repeating 40 cycles each of which comprises keeping at 94 °C for 30 seconds, at 55 °C for 30 seconds, and at 68 °C for 5 minutes.

Using the amplified and obtained DNA is used as a template, a ^{32}P -labeled probe may be produced employing Megaprime DNA-labelling system kit (Amersham Pharmacia Co.) and using the reaction solutions instructed by the kit. Using the probe obtained in such a manner, colony hybridization is carried out by a conventional method, practically the hybridization is carried out keeping at 65 °C in the presence of 6 × SSC (0.9 M NaCl and 0.09 M trisodium citrate), 5 × Denhard's solution [0.1% (w/v) ficoll 400, 0.1% (w/v) polyvinylpyrrolidone, 0.1% BSA], 0.5% (w/v) SDS and 100 $\mu\text{g/ml}$ degenerated salmon sperm DNA or in the DIG EASY Hyb solution (Boeringer-Mannheim Co.) containing 100 $\mu\text{g/ml}$ of degenerated salmon sperm DNA, successively keeping at a room temperature for 15 minutes two times in the presence of 1 × SSC (0.15 M NaCl and 0.015 M trisodium citrate) and 0.5% (w/v) SDS, and further keeping at 68 °C for 30 minutes in the presence of 0.1 × SSC (0.015 M NaCl and 0.0015 M sodium citrate) and 0.5% SDS to obtain clone hybridized with the probe.

Further, DNA coding the cytokinin receptor may be prepared based on, for example, the nucleotide sequence represented by SEQ ID No: 1, 3 or 5 by chemical synthesis of polynucleotides according to a common method such as phosphite-triester method (Hunkapiller, M. et al., Nature, 310, 105, 1984).

The DNA coding the cytokinin receptor obtained in such a manner may be cloned in a vector by a common method described in, "Molecular Cloning: A Laboratory Manual 2nd edition" (1989), Cold Spring Harbor Laboratory Press; "Current Protocols In Molecular Biology" (1987), John Wiley & Sons, Inc. ISBN-471-50338-X, and the like. The vector to be

used may be, for example, pBlue Script II vector (produced by Stratagene Co.), pUC18/19 vector (produced by Takara Shuzo Co., Ltd.), TA cloning vector (produced by Invitrogen Co.), and the like

Incidentally, the nucleotide sequence of cloned DNA may be confirmed by, the Maxam Gilbert method (described in, for example, Maxam, A., M & W. Gilbert, Proc. Natl. Acad. Sci. USA, 74, 560, 1977, and the like), the Sanger method (described in, for example, Sanger, F. & A.R. Coulson, J. Mol. Biol., 94, 441, 1975, Sanger, F. & Nicklen and A.R. Coulson., Proc. Natl. Acd. Sci. USA, 74, 5463, 1977, and the like). For the process, the following commercialized kits may be, for example, employed: Thermo Sequenase II dye terminator cycle sequencing kit (produced by Amersham Pharmacia Co.), Dye Terminator Cycle Sequencing FS Ready Reaction Kit (produced by PE Biosystems Japan Co.), and the like.

(3) Construction of expression vector

A expression vector of DNA coding the cytokinin receptor may be constructed according to a common method described in, for example, Molecular Cloning 2nd edition written by J., Sambrook, E., F., Frisch, & T., Maniatis, published by Cold Spring Harbor Laboratory Press.

Usable are vectors to be used in host cells to be transformed, for example, independently replicating vectors which contain genetic information possible to be duplicated in the host cells and further are possible to be isolated from the host cells and purified and may have detectable marker. More practically, in the case of using bacteria such as E. coli as the host cells, for example, Plasmid pUC 119 (produced by Takara Shuzo Co., Ltd.), Phagemid pBluescript II (Stratagene Co.) and the like may

be used. In the case of using yeast as the host cells, for example, Plasmid pACT2 (Clontech Co.) and the like may be used. In the case of using plant cells as the host cells, for example, DNA coding the cytokinin receptor may be integrated with Plasmid pBI221 (Clontech Co.) to construct the vectors.

A expression vector possible to express DNA coding the cytokinin receptor in a host cell may be constructed by integrating a promoter with the aforementioned vectors in the upstream of the DNA coding the cytokinin receptor in a binding manner of enabling to function in the host cell. In this case, the phrase, "in a binding manner of enabling to function", means that the promoter and the DNA coding the cytokinin receptor are bonded as to express the DNA coding the cytokinin receptor in the host cell under the control of the promoter. Usable as the promoter possible to function in the host cell in the case of using E. coli as the host cell are, for example, a promoter (*lacP*) of lactose operon of E. coli, a promoter (*trpP*) of triptophan operon, a promoter (*argP*) of arginine operon, a promoter (*galP*) of galactose operon, a tac-promoter, T7-promoter, T3-promoter, λ -phage promoter, (λ -pL, λ -pR) and the like. In the case of using yeast as the host cell, it may be prepared by a conventional genetic engineering method [described in Method in Enzymology 101 part (p.192-201) by Ammerer, et. al.] from ADHI promoter (the ADHI promoter is available from the yeast expression vector pAAH5 which contains the ADHI promoter and its terminator and which may be obtained from Washington Research Foundation). The ADHI promoter is included in US patent application number 299,733 of Washington Research Foundation and in the case that it is used for industrial and commercial purposes in USA., it is required to obtain

30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

permission from the patent holder. In the case of using a plant cell as the host cell, usable examples are a nopaline synthesis enzyme gene (NOS) promoter, an octopine synthesis enzyme gene (OCT) promoter, a cauliflower mosaic virus (CaMV)-derived 19S promoter, a CaMV-derived 35S promoter and the like.

Further, in the case of integrating DNA coding the cytokinin receptor with a vector previously having a promoter possible to function in a host cell, DNA coding the cytokinin receptor is inserted in the downstream of the promoter and the DNA coding the cytokinin receptor in a manner of enabling to function. For example, the aforementioned plasmid pACT 2 for yeast comprises the ADH1 promoter and therefore, an expression vector possible to express the DNA coding the cytokinin receptor in yeast, for example, CG1945 (Clontech Co.) may be constructed by inserting the DNA coding the cytokinin receptor in the downstream of the ADH1 promoter of the plasmid pACT2.

(4) Production of transformed cell

A transformed cell to be used for the present invention may be produced by introducing the constructed expression vector into a host cell by a conventional method. As the host cell to be used for production of the transformed cell, examples are bacteria, yeast, plant cell and the like. As bacteria, examples are bacteria belonging to *E. coli*, *Serratia*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Microbacterium* and the like. As yeast, examples are budding yeast and fission yeast. More particularly, examples are yeast belonging to *Saccharomyces*, *Schizosaccharomyces* and the like. As plant cell, examples are BY-2 strain, which is a cultured cell of tobacco

and BMS strain, which is a cultured cell of corn (Black Mexican Sweet), and the like.

The method for introducing the expression vector into the aforementioned host cell includes a conventional introduction method to be employed corresponding to the host cell to be transformed. For example, in the case of using bacteria as the host cell, the aforementioned expression vector may be introduced into a host cell by employing a conventional introduction method such as a calcium chloride method and an electroporation method described in, "Molecular Cloning" (by J. Sambrook, et. al Cold Spring Harbor 1989). In the case of using yeast as a host cell, the aforementioned expression vector may be introduced into the host cell by employing Yeast transformation kit (produced by Clontech Co.) based on a lithium method. Further, in the case of using a plant cell as a host cell, the aforementioned expression vector may be introduced into the host cell by a conventional introduction method, for example, Agrobacterium infection method (Japanese Examined Patent Application No. 2 - 58917, Japanese Laid-Open Patent Application No. 60 - 70080), an electroporation method into a protoplast (Japanese Laid-Open Patent Application No. 60 - 251887, Japanese Laid-Open Patent Application No. 5 - 68575), a particle gun method (Japanese Laid-Open Patent Application No. 6 - 508316, Japanese Laid-Open Patent Application No. 63 - 258525).
(Transformed cell in which a cytokinin receptor of partially transmembrane region-deleted type, i.e. a cytokinin receptor of a transmembrane time variation type, is expressed)

A cytokinin receptor to be used for the present invention includes a

cytokinin receptor wherein said cytokinin receptor has at least one transmembrane region but less than that in its natural form (commonly 2 to 4 transmembrane region) (incidentally, in the present invention, such cytokinin receptors are sometimes referred as to cytokinin receptors of partially transmembrane region-deleted type.) In this case, the phrase, "its natural form" means cytokinin receptors having an amino acid sequence most frequently existing among organisms having the similar nomenclature and generally called also as wild-type cytokinin receptor.

Such cytokinin receptors of partially transmembrane regions-deleted type are cytokinin receptors whose transmembrane region structure may be assumed by employing structure assumption software available in http://www.ch.embnet.org/software/TMPRED_form.html and whose transmembrane regions are partially deleted, for example, in 1 to 2 sites and are less in number than the number of the transmembrane regions of the natural type cytokinin receptors (i.e. natural form).

More particularly, examples of such cytokinin receptors include a cytokinin receptor having the amino acid sequence from amino acid number 196 to 1176 among the amino acid sequence represented by SEQ ID No: 2 (2 transmembrane regions); a cytokinin receptor having the amino acid sequence from amino acid number 50 to 1176 among the amino acid sequence represented by SEQ ID No: 2 (3 transmembrane regions); a cytokinin receptor having the amino acid sequence from amino acid number 32 to 1036 among the amino acid sequence represented by SEQ ID No: 4 (3 transmembrane regions); a cytokinin receptor having the amino acid sequence derived from the amino acid sequences of these cytokinin receptors

wherein one or a plurality of amino acids are deleted, substituted or added, for example, cytokinin receptors having the amino acid sequence derived from the amino acid sequences in which one methionine is added to the amino-terminal and the like.

The DNA coding the cytokinin receptor may be constructed as to hold transmembrane regions in a less number than the number of the transmembrane regions of the natural type cytokinin receptors by partially deleting the transmembrane regions by a conventional genetic engineering technique.

Production of the transformed cell in which the DNA coding the cytokinin receptor is introduced may be carried out according to the aforementioned method, "Production of transformed cell in which the DNA coding a cytokinin receptor is introduced".

(Transformed cell to express chimera-type cytokinin receptor)

A cytokinin receptor to be used in the present invention also includes a chimera-type cytokinin receptor comprising extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, and histidine kinase regions of the cytokinin receptor, wherein each of the regions is a homogeneous region to one another and receiver regions for the histidine kinase, which are heterogeneous regions to these regions.

In the above, histidine kinase regions of the cytokinin receptor means, for example, a region existed at the C-terminal side of a transmembrane regions located in the N-terminal side of the cytokinin receptor, and said region having five conservative motifs which are common

to generic histidine kinases as described in Annual Review of Genetics 23:311-336 (1989), Microbiological Reviews 53(4):450-490(1989), Science 262:539-544(1993), and the like. Examples of the region includes a region having the amino acid sequence from amino acid number 587 to 844 among the amino acid sequence represented by SEQ ID No: 2 in a case of AHK2, a region having the amino acid sequence from amino acid number 450 to 700 among the amino acid sequence represented by SEQ ID No: 4 in a case of AHK3 and a region having the amino acid sequence from amino acid number 449 to 714 among the amino acid sequence represented by SEQ ID No: 6 in a case of CRE1.

Receiver regions of the cytokinin receptor means, for example, a region existed between the histidine kinase region and the C-terminal end of the cytokinin receptor, and said region having three conservative motifs which are common to generic histidine kinases as described in Annual Review of Genetics 23:311-336 (1989), Science 262:539-544(1993), and the like. Examples of the region includes a region having the amino acid sequence from amino acid number 891 to 1163 among the amino acid sequence represented by SEQ ID No: 2 in a case of AHK2, a region having the amino acid sequence from amino acid number 746 to 1018 among the amino acid sequence represented by SEQ ID No: 4 in a case of AHK3 and a region having the amino acid sequence from amino acid number 763 to 1038 among the amino acid sequence represented by SEQ ID No: 6 in a case of CRE1.

In addition, a sensor region for cytokinin means, for example, a region which is a part of any of the extracellular regions of the cytokinin

receptor, said region existed between a transmembrane region next to the histidine kinase region and a transmembrane region secondary close to the histidine kinase region, and said region have 50% and more identification and homology between three cytokinin receptors of AHK2, AHK3 and CRE1 as described in Plant and Cell Physiology 42(2):231-235(2001) and the like. Examples of the region includes a region having the amino acid sequence from amino acid number 259 to 536 among the amino acid sequence represented by SEQ ID No: 2 in a case of AHK2, a region having the amino acid sequence from amino acid number 120 to 399 among the amino acid sequence represented by SEQ ID No: 4 in a case of AHK3 and a region having the amino acid sequence from amino acid number 132 to 398 among the amino acid sequence represented by SEQ ID No: 6 in a case of CRE1.

The histidine kinase has the following sequence in common in plants, e.g. higher plants, and microorganism. That is, histidine kinase is composed of extracellular regions, transmembrane regions (generally about 2 to 4), histidine kinase regions having histidine kinase activity and holding Histidine residue to be an active site, and receiver regions having a reception part for phosphate group transfer and holding Aspartic acid residue to be an active site. In the chimera-type cytokinin receptor, it is important that the extracellular regions, transmembrane regions, and histidine kinase regions are all derived from the same cytokinin receptor, whereas the receiver regions are derived differently from the former cytokinin receptor.

It is sufficient for the receiver regions of the chimera-type cytokinin receptor to have a function of receiving signals transmitted from the

histidine kinase regions and transmitting them to the next step and any may be usable as long as they can complement or improve the intrinsic functions of the receiver regions of histidine kinase comprising the homogeneously derived extracellular regions, transmembrane regions, and histidine kinase regions.

As such receiver regions, usable are, for example, receiver regions of histidine kinase derived from microorganism (e.g. receiver regions of histidine kinase derived from microorganism such as yeast, E. coli) and more particularly receiver regions of histidine kinase coded in Sln1 gene derived from budding yeast (e.g. the amino acid sequence represented by SEQ ID No: 7), receiver regions of histidine kinase coded in Chey gene derived from Salmonella, receiver regions of histidine kinase coded in RcsC gene, which is a hybrid sensor of E. coli [Maeda T, et al. Nature: 369 242-245, (1994); e.g. the amino acid sequence represented by SEQ ID No: 8], receiver regions of histidine kinase coded in Phks gene relevant to cell cycle control of fission yeast [Shieh, JC, et al., Gene Dev. 11, 1008-1022(1997)].

The DNA coding the chimera-type cytokinin receptor may be constructed by respectively producing DNA for each of the extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, histidine kinase regions of the cytokinin receptor, and receiver regions for the histidine kinase, joining the DNA by a common genetic engineering technique so as to prevent appearance of any termination codon in the middle while using a proper linker so as to prevent frame shift. Incidentally, the DNA may be produced as one DNA fragment for the extracellular regions of the cytokinin receptor and transmembrane regions

5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

of the cytokinin receptor or for extracellular regions of the cytokinin receptor, transmembrane regions of the cytokinin receptor, and histidine kinase regions of the cytokinin receptor.

The polynucleotides coding the aforementioned respective regions may respectively be produced by known methods. For example, in the case of production by PCR, at first, the oligonucleotides (5' side primers) having the nucleotide sequences of 5' terminal regions of respective regions to be amplified and oligonucleotides (3' side primers) having complementary nucleotide sequences to the nucleotide sequences of 3' terminal are designed and synthesized. The primers may be oligonucleotides of about 14 nucleotides to about 35 nucleotides in general and are preferable to contain restriction enzyme recognition sequences usable at the time of ligating the polynucleotides amplified by the PCR to one another or these polynucleotides to vectors in the 5' side of the primers. Then, using the primers and the cDNA library as a template, amplification reactions may be carried out in the common reaction conditions employed for the PCR. As the template to be used in the case of producing the polynucleotides coding the extracellular regions through the transmembrane regions of the cytokinin receptor or the histidine kinase regions of the cytokinin receptor, usable is cDNA library derived from plants such as higher plants. Also as the template to be used in the case of producing the polynucleotides coding the receiver regions of the histidine kinase, usable is cDNA library derived from microorganism prepared by a common method or the total DNA.

The production of the transformed cell in which the DNA coding the chimera-type cytokinin receptor is introduced may be carried out according

to the aforementioned, "Production of the transformed cell in which the DNA coding a cytokinin receptor is introduced".

(Intracellular signal transduction system relevant to cytokinin)

Measurement of the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell produced by the above-described manner in the present invention may be carried out by utilizing the intracellular signal transduction system which the host cell used for production of the transformed cell originally has. The phrase, "the existence or the quantity of intracellular signal transduction" means, for example, the quantity of the cell growth of the transformed cell as an indicator. Alternatively, a regulator and/or a mediator having the intracellular signal transduction function, so-called Two-Component regulatory system, is introduced and expressed in the host cell and the expressed system may be used as the intracellular signal transduction system. Usable as the Two-Component regulatory system, for example, are Two-Component regulatory systems corresponding to 5 types of ethylene receptors; ETR1, ETR2, ERS1, ERS2, and EIN4; which *Arabidopsis* has [Chang et al., *Science* 262: 539-544 (1993), Hua et al., *Science* 269: 1712-1714 (1995), Sakai et al., *Plant Cell Physiol* 39: 1232-1239 (1998)] and AtHK1 having sensor functions to the osmotic pressure [Urao, *Plant Cell* 11: 1743-1754 (1999)].

As the host cell to be used for production of such a transformed cell, usable are host cells improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cells. For example, it

includes the host cells improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell by deleting one or more of histidine kinases. The phrase, "histidine kinase activity lower than" means that the quantity of phosphate group transfer from Histidine residue to be an active site of histidine kinase regions having histidine kinase activity to Aspartic acid residue to be an active site of receiver regions having a reception part has decreased. The state causes change of the quantity of the cell growth, change of the morphology, change of the shape, change of the quantity of the biosynthesis of specific compound, change of the quantity of the metabolism of specific compound in the transformed cell so improved as to have histidine kinase activity lower than the intrinsic histidine kinase activity of the host cell. More particularly, the following strain [Maeda T et al., Nature 369: 242-245 (1994)] may be exemplified: a strain obtained by defecting the Sln1 gene coding the protein having the osmotic pressure sensor function and derived from the budding yeast such as *Saccharomyces cerevisiae* and the like. Since the strain has decreased quantity of the cell growth in the cause of being defected in the histidine kinase existing in *Saccharomyces cerevisiae*, it can more clearly detect the existence or the quantity of the intracellular signal transduction from the cytokinin receptor expressed in the transformed cell by using the quantity of the cell growth of the transformed cell as an indicator. Further, other preferable example includes a defective strain of the RcsC gene, which is a hybrid sensor derived from *E. coli* and a defective strain of Phks gene relevant to the cell cycle control of fission yeast.

(Method for analyzing agonist-activity and antagonist-activity to a cytokinin

receptor)

In the method for analyzing agonist-activity to a cytokinin receptor, examples of the first step of bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced include a method for culturing the transformed cell in a culture medium containing the examinee substance. In order to culture the transformed cell, both cultures are usable: liquid-phase culture for culturing the transformed cell in a liquid culture medium and a solid-phase culture for culturing the transformed cell in a solid culture medium produced by adding agar or the like to the liquid culture medium. The concentration of an examinee substance in the culture medium is about 1 nM to about 1 mM and preferably about 10 nM to about 100 μ M. The culture time is, for example, 1 hour or longer and 3 days and preferably 25 hours to 2 days. Incidentally, in the case of method for analyzing the agonist-activity to the cytokinin receptor, the culture containing no cytokinin may be used as the culture containing the examinee substance.

In the method for analyzing the antagonist-activity to the cytokinin receptor, examples of the first step of bringing an examinee substance and a substance having the agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced include a method for culturing the transformed cell in a culture medium containing the examinee substance and a substance having the agonist-activity to the cytokinin receptor. In order to culture the transformed cell, both cultures are usable: liquid-phase culture for culturing the transformed cell in a liquid culture medium and a solid-phase culture

for culturing the transformed cell in a solid culture medium produced by adding agar or the like to the liquid culture medium. The concentration of an examinee substance in the culture medium is about 1 nM to about 1 mM and preferably about 10 nM to about 100 μ M. The concentration of the substance (e.g. cytokinins such as trans-zeatin, cis-zeatin, benzyl adenine, thidiazuron and the like) having the agonist-activity to the cytokinin receptor is about 1 nM to about 1 mM and preferably about 10 nM to about 100 μ M. The culture time is, for example, 1 hour or longer and 3 days and preferably 25 hours to 2 days. Incidentally, in the case of method for analyzing the agonist-activity to the cytokinin receptor, the culture containing no cytokinin may be used as the culture containing the examinee substance.

The agonist-activity or the antagonist-activity of an examinee substance to the cytokinin receptor may be detected by evaluating the agonist-activity of two or more different examinee substances to the cytokinin receptor based on the difference obtained by comparison of the existence and the quantity of the intracellular signal transduction in a region where the examinee substances (preferable is, for example, between at least two or more different examinee substances, at least one has no agonist-activity or antagonist-activity to the cytokinin receptor) are independently used and measured by the aforementioned method for analyzing the agonist-activity or the antagonist-activity to the cytokinin receptor.

More particularly, for example, in the case of using a transformed cell (that is, a transformed cell having a function of directly controlling the

抄録

cell growth by intracellular signal transduction from the cytokinin receptor) produced using TM182 (Sln1 Δ) [Maeda T et al, Nature 369: 242-245 (1994)], a Sln1 genetically defected strain in which, for example, PTP2 Tyrosine phosphatase gene [Ota et al. Proc. N. A. Sci., USA, 89, 2355-2359 (1992)] is introduced as a host cell, the agonist-activity to the cytokinin receptor may be measured using, as an indicator, the quantity of the cell growth of the transformed cell in a culture medium (an agar culture medium or a liquid culture medium) containing glucose as a carbon source, for example, a DOLU · Gul culture medium. In this case, if into the DOLU + Gul culture medium is added the examinee substance and no substance having the agonist-activity to the cytokinin receptor, the examinee substance found capable of growing the transformed cell can be evaluated as a substance having the agonist-activity to the cytokinin receptor. On the other hand, if into the DOLU+GUL culture medium is added the examinee substance and a substance having the agonist-activity to the cytokinin receptor, the examinee substance found capable of suppressing or inhibiting the growth of the transformed cell can be evaluated as a substance having the antagonist-activity to the cytokinin receptor.

Incidentally, as a blank, investigation may be carried out to find the growth of the transformed cell in a culture medium using galactose as the carbon source in place of glucose, for example, a DOLU + Gal culture medium, independently of the existence of the examinee substance.

Further, in the case of using a transformed cell produced by employing fission yeast, which is a Phks genetically defected strain, as a

host cell (that is, a transformed cell having a function of directly controlling the cell growth by the intracellular signal transduction from the cytokinin receptor), the fission pattern of the fission yeast may be observed with a microscope. In this case, if the culture medium contains the examinee substance and no substance having the agonist·activity to the cytokinin receptor, the examinee substance found capable of normal fission and propagation of the transformed cell can be evaluated as a substance having the agonist·activity to the cytokinin receptor. On the other hand, if the culture medium contains an examinee substance and a substance having the agonist·activity to the cytokinin receptor, the examinee substance found capable of suppressing or inhibiting the normal fission and propagation of the transformed cell can be evaluated as a substance having the antagonist·activity to the cytokinin receptor.

Furthermore, in the case of using a transformed cell produced by employing *E. coli* defective in RcsC gene into which cps·LacZ is introduced as a host cell (that is, a transformed cell having a function of directly controlling reporter gene expression by the intracellular signal transduction from the cytokinin receptor), the X-Gal coloring may be observed in an agar culture medium or a liquid culture medium [Suzuki et al. Plant Cell Physiol 42: 107-113 (2001)]. In this case, if the culture medium contains the examinee substance and no substance having the agonist·activity to the cytokinin receptor, the examinee substance found capable of coloring the transformed cell to be blue can be evaluated as a substance having the agonist·activity to the cytokinin receptor. On the other hand, if the culture medium contains the examinee substance and a substance having the

agonist-activity to the cytokinin receptor, the examinee substance found capable of disappearing coloring the blue of the transformed cell can be evaluated as a substance having the antagonist-activity to the cytokinin receptor.

Moreover, an agonist-active substance or an antagonist-active substance to the cytokinin receptor may be searched by selecting substances having the agonist-active substance or the antagonist-active substance to the cytokinin receptor based on the agonist-activity or the antagonist-activity to the cytokinin receptor evaluated by the aforementioned detection methods.

Further, a substance selected by the above described detection methods may be utilized as an active ingredient of a plant growth regulator.

The plants to be the objects to be treated with the aforementioned plant growth regulator are, for example, decorative plants such as flowering plants and ornamental foliage plants; cultivating plants such as crop, vegetable, fruit and the like; fibrous plants; trees; lawn and the like.

The growth regulator is generally mixed with a solid carrier, a liquid carrier, and the like and further, if needed, mixed with a surfactant and other auxiliary agents for the formulation of an agricultural and horticultural agent and formulated in an emulsion agent, a hydrating agent, a suspension agent, a solution agent and the like. In these agricultural and horticultural agents, an agonist-active substance or an antagonist-active substance to the cytokinin receptor may be contained generally in 0.5 to 90 % by weight and preferably in 1 to 80 % by weight.

Usable as the solid carrier to be used for the formulation of an

agricultural and horticultural agent are, for example, clays (kaolinite, kieselguhr, synthesized hydrated silicon oxide, intercalated clays, bentonite, acidic white clay, and the like), talc, other inorganic minerals (sericite, quartz powder, sulfur powder, activated carbon, calcium carbonate, and the like), chemical fertilizers (ammonium sulfate, ammonium phosphate, ammonium nitrate, ammonium chloride, urea, and the like) in finely powdered state or in granular state and usable as the liquid carrier are, for example, water, alcohols (methanol, ethanol and the like), ketones (acetone, methyl ethyl ketone, cyclohexanone and the like), aromatic hydrocarbons (toluene, xylene, ethylbenzene, methylnaphthalene and the like), non-aromatic hydrocarbons (hexane, cyclohexane, kerosene and the like), esters (ethyl acetate, butyl acetate and the like), nitriles (actonitrile, isobutylnitrile and the like), ethers (dioxane, diisopropyl ether and the like), acid amides (dimethylformamide, dimethylacetamide and the like), halohydrocarbons (dichloroethane, trichloroethane and the like), etc.

As the surfactant, usable are, for example, alkylsulfuric acid esters, alkylsulfonic acid salts, alkylarylsulfonic acid salts, alkylaryl ethers and their polyoxyethylene compounds, polyethylene glycols, polyhydric alcohol esters, sugaralcohols and the like.

As other auxiliary agents for the formulation of agricultural and horticultural agents, usable are solidification agents and dispersants such as casein, gelatin, polysaccharides (starch, acacia, cellulose derivatives, alginic acid and the like), lignin derivatives, bentonite, synthesized water-soluble polymer [poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(acrylic acid) and the like] and the like, and stabilizers such as PAP

(acidic isopropyl phosphate), BHT (2,6-tert-butyl-4-methylphenol), BHA (2-/3-tert-butyl-4-methoxyphenol), plant oils, mineral oils, aliphatic acids, aliphatic acid esters and the like.

The agonist-active substance or the antagonist-active substance to the cytokinin receptor made to be agricultural and horticultural agents is used as it is or diluted with water to carry out treatment for the stem and leave parts, branch and leave parts, and flower and fruit parts of plants by spraying, for fruits by immersion, and for fruits by application. The plant growth regulator is used for the object plants to carry out the treatment once or a plurality of times.

In the case of using the plant growth regulator for the purpose of suppressing the dropping of fruits, the plant growth regulator is diluted with water and the resulting diluted agent is sprayed to the fruit parts and branch and leave parts before harvest.

In the case of using the plant growth regulator for the purpose of suppressing the ball dropping of cotton, the plant growth regulator is diluted with water and the resulting diluted agent is sprayed to the balls and stem and leave parts of cotton before harvest.

The plant growth regulator may be used for the treatment of growing plants or of plants after harvest.

The application amount of the agonist-active substance or the antagonist-active substance to the cytokinin receptor in an agricultural and horticultural agent is generally 1 to 8000 g per 1 hectare, although it is changed depending on the state of the agricultural and horticultural agent, the timing for the treatment, the method for the treatment, the site for the

treatment, and the object plant to be treated. Also in the case of using the plant growth regulator while diluting the agent with water, the concentration of the agent is generally 0.0001 to 1000 mM and preferably 0.001 to 10 mM, although it is changed depending on the state of the agricultural and horticultural agent, the timing for the treatment, the method for the treatment, the site for the treatment, and the object plant to be treated.

Next, hereinafter given are formulation examples of an agricultural and horticultural agent produced from an agonist-active substance or an antagonist-active substance to the cytokinin receptor and used as a plant growth regulator. The parts in the following description of the examples denotes the parts by weight.

Formulation example 1

A hydrating agent was obtained by sufficiently pulverizing and mixing 50 parts of an agonist-active substance or an antagonist-active substance to the cytokinin receptor, 3 parts of calcium ligninsulfonate, 2 parts of sodium laurylsulfate, and 45 parts of synthesized hydrated silicon oxide.

Formulation example 2

A hydrating agent was obtained by sufficiently pulverizing and mixing 70 parts of an agonist-active substance or an antagonist-active substance to the cytokinin receptor, 3 parts of calcium ligninsulfonate, 2 parts of sodium laurylsulfate, and 25 parts of synthesized hydrated silicon oxide.

Formulation example 3

An emulsion agent was obtained by mixing 40 parts of an agonist-active substance or an antagonist-active substance to the cytokinin receptor, 3 parts of polyoxyethylene sorbitane monoolate, 2 parts of CMC (carboxymethyl cellulose), and 52 parts of water and wet-pulverizing the resultant mixture to be 5 μ m or smaller in the particle size.

The present invention makes it possible to analyze the agonist-activity and the antagonist-activity to the cytokinin receptor and also makes it possible to quickly search the substances having the agonist-activity and the antagonist-activity to the cytokinin receptor even in a small amount of examinee substances by employing the analysis method.

EXAMPLES

Hereinafter, although the present invention will be described in details with the reference to examples, the present invention is not at all restricted to these examples.

(Example 1) Production of *Arabidopsis* cDNA phage library for CRE1 cloning

Seeds of *Arabidopsis thaliana* ecotype Wassilewskija were sterilized with 70% of ethyl alcohol for 1 minute and further sterilized with 1.5% of sodium hypochlorite for 10 minutes. The resulting seeds were well washed with sterilized water and then cultured for 2 weeks in GM culture medium [4.3 g Murashige and Skoog's basal salt mixture, 1% sucrose, 10 ml of 5% MES-KOH (pH 5.7), 0.3% PhytagelTM (SIGMA)] to obtain 5g of the plant. After the plant was frozen in liquefied nitrogen and physically milled with a mortar and a pestle. The resulting milled product was mixed with a mixed solution of 10 ml of an extraction buffer [200 mM Tris-HCl (pH 8.5), 100 mM

NaCl, 10 mM EDTA, 0.5% SDS, 14 mM β -mercaptoethanol] and 10 g of phenol. After being mixed by a Voltex mixer, the resulting mixture was mixed further with 10 ml of chloroform and vigorously stirred and subjected to centrifugal separation at 10,000 rotation for 20 minutes. The recovered aqueous layer was mixed with LiCl in the concentration to be 2M of the final concentration, left still at -80°C for 3 hours, thawed and subjected to centrifugal separation at 10,000 rotation for 20 minutes to recover a precipitate. The recovered precipitate was dissolved in 2 ml of TE [10 mM Tris-HCl (pH 8.0), 1 mM EDTA] and then further mixed with 0.2 ml of 3 M sodium acetate (pH 5.2) and 5 ml ethanol and subjected to centrifugal separation to recover RNA as a precipitate. Further, the precipitate (RNA) was subjected to treatment with OligotexTM dT30super (Nippon Rosch Co.) to extract RNA integrated with polyA.

The production of phage cDNA library from the extracted RNA integrated with polyA was carried out employing ZAP-cDNAR Synthesis Kit (Stratagene Co.) according to the instruction. The potency of the produced phage cDNA library was 500,000 PFU.

(Example 2) Production of DNA probe of CRE1

The PCR was carried out employing TAKARA LA TaqTM (Takara Shuzo Co., Ltd.) and using a phage solution (about 1,000,000 PFU) of the phage cDNA library produced in the example 1 as a template and DNA having the nucleotide sequence represented by SEQ ID No: 11 and DNA having the nucleotide sequence represented by SEQ ID No: 12 as the primers to amplify DNA. The procedure will be described in details below.

A PCR solution was prepared by adding a reaction composition

J P D C S E R T

containing dNTP and the like to the phage 1,000,000 pft and respective primer DNA each in 0.2 μ M according to the instruction of the kit and the desired DNA fragment was amplified in PCR conditions: keeping at 94°C for 2 minutes, and further repeating 40 cycles each of which comprised keeping at 94°C for 30 seconds, at 55°C for 30 seconds, and at 68°C for 5 minute.

Next, using the amplified DNA fragment as a template, a probe labelled with 32 P was prepared employing Megaprime DNA-labelling system kit (Amersham Pharmacia Co.). Incidentally, reaction solution (25 μ l) was prepared by adding 2.0 MBq of 32 P dCTP to 25 ng of amplified DNA fragment and adding a reaction composition instructed by the kit. The labelling reaction was carried out at 37°C for 10 minutes.

(Example 3) Production of phage cDNA clone holding CRE1

The cloning of desired CRE1 gene was carried out by plaque hybridization using the probe prepared by the example 1. Detailed description will be given below.

Using the phage cDNA library produced in the example 1 and according to the instruction of ZAP-cDNAR Synthesis Kit, plaque was produced. DNA was adsorbed on a nitrocellulose filter from the produced plaque and then treated with UV rays to be fixed on the filter. Using the filter prepared in such a manner, hybridized phage cDNA clone was obtained by keeping at 65°C in the presence of 6 \times SSC (0.9 M NaCl and 0.09 M trisodium citrate), 5 \times Denhard's solution [0.1% (w/v) ficoll 400, 0.1% (w/v) polyvinylpyrrolidone, 0.1% BSA], 0.5% (w/v) SDS and 100 μ g/ml degenerated salmon sperm DNA or in DIG EASY Hyb solution (Boeringer-Mannheim Co.) containing 100 μ g/ml of degenerated salmon

sperm DNA, successively keeping at a room temperature for 15 minutes two times in the presence of 1 × SSC (0.15 M NaCl and 0.015 M trisodium citrate) and 0.5% (w/v) SDS, and further keeping at 68°C for 30 minutes in the presence of 0.1 × SSC (0.015 M NaCl and 0.0015 M trisodium citrate) and 0.5% SDS.

(Example 4) Cloning of CRE1 cDNA

Using the cDNA of the phage cDNA clone obtained by the example 3 as a template and DNA having the nucleotide sequence represented by SEQ ID No: 13 and DNA represented by SEQ ID No: 14 as primers, DNA having the nucleotide sequence represented by SEQ ID No: 5 was amplified by PCR. Detailed description will be given below.

The PCR was carried out employing Herculase Enhanced DNA Polymerase (TOYOBO Co., Ltd.) in the reaction conditions of keeping at 94°C for 1 minute, and further repeating 25 cycles each of which comprised keeping at 94°C for 30 seconds, at 55°C for 30 seconds, and at 72°C for 4 minute. Incidentally, the PCR solution (50 μl) was prepared by adding a reaction composition containing dNTP and the like to 500 ng of cDNA of the phage cDNA clone and respective primer DNA each in 100 ng according to the instruction of the kit.

The desired DNA fragment was amplified in such a manner.

(Example 5) Construction of CRE1 expression vector

After p415CYC1, a yeast expression vector, [Munberg et al. Gene: 156 119-122 (1995), available from ATCC library (No. 873821)] was digested with a restriction enzyme Sma I and then using T4 DNA ligase, DNA having the nucleotide sequence represented by SEQ ID No: 5 and obtained

by the example 3 was ligated downstream of the CYC 1 promoter sequence of the expression vector p415CYC1 as to be integrated to express the desired protein in yeast. The constructed DNA was confirmed to be in the right direction and its nucleotide sequence was confirmed to be the nucleotide sequence represented by SEQ ID No: 6 by an automatic DNA sequencer and then the expression plasmid p415CYC-CRE 1 was obtained.

(Example 6) Cloning of AHK3 (AAF99730) cDNA

Seeds of *Arabidopsis thaliana* ecotype Wassilewskija were sterilized with 70% of ethyl alcohol for 1 minute and further sterilized with 1.5% of sodium hypochlorite for 10 minutes. The resulting seeds were well washed with sterilized water and then cultured for 2 weeks in GM culture medium [4.3 g Murashige and Skoog's basal salt mixture, 1% sucrose, 10 ml of 5% MES-KOH (pH 5.7), 0.3% PhytagelTM (SIGMA)] to obtain 5g of the plant. After the plant was frozen in liquefied nitrogen and physically milled with a mortar and a pestle. The resulting milled product was mixed with a mixed solution of 10 ml of an extraction buffer [200 mM Tris-HCl (pH 8.5), 100 mM NaCl, 10 mM EDTA, 0.5% SDS, 14 mM β -mercaptoethanol] and 10 g of phenol. After being mixed by a Voltex mixer, the resulting mixture was mixed further with 10 ml of chloroform and vigorously stirred and subjected to centrifugal separation at 10,000 rotation for 20 minutes. The recovered aqueous layer was mixed with LiCl in the concentration to be 2M of the final concentration, left still at -80°C for 3 hours, thawed and subjected to centrifugal separation at 10,000 rotation for 20 minutes to recover a precipitate. The recovered precipitate was dissolved in 2 ml of TE [10 mM Tris-HCl (pH 8.0), 1 mM EDTA] and then further mixed with 0.2 ml of 3 M

PCT/JP2008/050002

sodium acetate (pH 5.2) and 5 ml ethanol and subjected to centrifugal separation to recover RNA as a precipitate. Further, 40 μ g of the precipitate (RNA) was mixed with 30 unit of FPLC pureTM DnaseI (Amersham-Pharmacia) and 60 unit of Superace (Ambion) to remove mixed genome DNA and the resulting RNA was subjected to the phenol/chloroform treatment and ethanol treatment to purify the RNA. Next, using the purified RNA as a template and oligo (dT) 12-18 (Amersham-Pharmacia) as a primer, RT-PCR was carried out. The RT-PCR was carried out employing Superscript II (GIBCO BRL Co.) at 42°C for 40 minutes. Incidentally the PT-PCR solution was prepared according to the method described in instruction of the Superscript II.

The desired cDNA was amplified in such a manner.

Using the amplified cDNA as a template and DNA having the nucleotide sequence represented by SEQ ID No: 16 and DNA having the nucleotide sequence represented by SEQ ID No: 17 as primers, DNA having the nucleotide sequence represented by SEQ ID No: 3 was amplified by PCR. The PCR was carried out using Herculase Enhanced DNA Polymerase (TOYOBO Co., Ltd.) in the reaction conditions of keeping at 94°C for 1 minute, and further repeating 41 cycles each of which comprised keeping at 94°C for 30 seconds, at 55°C for 30 seconds, and at 72°C for 4 minute. Incidentally, the PCR solution (50 μ l) was prepared by adding a reaction composition containing dNTP and the like to 500 ng of the template DNA and respective primer DNA each in 100 ng according to the instruction of the kit.

The desired DNA fragment was amplified in such a manner.

(Example 7) Construction of pHM·1

After p415CYC1 [Munberg et al. Gene: 156 119-122 (1995); available from ATCC library (No. 87382)] was digested with the restriction enzyme Spe I and BamH I, synthesized DNA fragments (linkers) having the nucleotide sequence represented by SEQ ID Nos: 18 and 15 were inserted to the expression vector p415CTC1 using T4 DNA ligaseas to newly add the restriction enzyme sites Sac II, Apa I, Nhe I to the plasmid p415CYC1 and construct pHM·1.

(Example 8) Construction of AHK3 expression vector

After the pHM·1 was digested with the restriction enzyme Sal I and Sac II, and then using T4 DNA ligase, DNA having the nucleotide sequence represented by SEQ ID No: 3 was introduced downstream of the CYC1 promoter sequence of the expression vector pHM·1 as to be integrated to express the desired protein in yeast. The constructed DNA was confirmed to be right in the direction and its nucleotide sequence was confirmed to be right in the sequence by an automatic DNA sequencer and thus the expression plasmid p415CYC·AHK3 was obtained.

(Example 9) Cloning of AHK2(BAB09274)cDNA

Using the DNA fragments obtained by the example 6 (the cDNA prepared by reverse transcription of the total RNA) as a template and DNA having the nucleotide sequence represented by SEQ ID No: 19 and DNA having the nucleotide sequence represented by SEQ ID No: 20 as primers, DNA having the nucleotide sequence represented by SEQ ID No: 1 was amplified by PCR. The PCR was carried out employing TAKARA Pfu Turbo denature (Takara Shuzo Co., Ltd.) in the reaction conditions of

keeping at 94°C for 1 minute, and further repeating 30 cycles each of which comprised keeping at 94°C for 30 seconds, at 55°C for 30 seconds, and at 72°C for 4 minute. Incidentally, the PCR solution (50 μ l) was prepared by adding a reaction composition containing dNTP and the like to 500 ng of the template DNA and respective primer DNA each in 50 ng according to the instruction of the kit.

The desired DNA fragment was amplified in such a manner.

(Example 10) Cloning of AHK2(BAB09274) Δ cDNA

Using the DNA fragments obtained by the example 6 (the cDNA prepared by reverse transcription of the total RNA) as a template and DNA having the nucleotide sequence represented by SEQ ID No: 21 and DNA having the nucleotide sequence represented by SEQ ID No: 22 as primers, PCR was carried out to amplify DNA having the nucleotide sequence represented by SEQ ID No: 1 in which ATG was added to the 5' terminal sites of the nucleotide sequence from the nucleotide numbers 586 to 3531. The PCR was carried out employing TAKARA Pfu Turbo denature (Takara Shuzo Co., Ltd.) in the reaction conditions of keeping at 94°C for 1 minute, and further repeating 30 cycles each of which comprised keeping at 94°C for 30 seconds, at 55°C for 30 seconds, and at 72°C for 4 minute. Incidentally, the PCR solution (50 μ l) was prepared by adding a reaction composition containing dNTP and the like to 500 ng of the template DNA and respective primer DNA each in 50 ng according to the instruction of the kit.

The desired DNA fragment was amplified in such a manner.

(Example 11) Construction of AHK2 and AHK2 Δ expression vector

After pHM-1 was digested with a restriction enzyme Sac II and Nhe

I and then using T4 DNA ligase, DNA fragments obtained by the example 9 and the example 10 were respectively ligated downstream of the CYC 1 promoter sequence of the expression vector pHM-1 as to be integrated to express the desired protein in yeast. The introduced DNA was confirmed to be right in the direction and its nucleotide sequence was confirmed to be right in the sequence by an automatic DNA sequencer and thus the expression plasmid p415CYC-AHK 2 and p415CYC-AHK2 Δ were obtained.

(Example 12) Production of transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3

Transformation of TM182 (Sln1 Δ), Sln1 genetically detected strain, [Maeda T et al. Nature: 369 242-245 (1994)] was carried out using the obtained expression plasmid p415CYC-CRE1 (the example 5), p415CYC-AHK2 (the example 11), p415CYC-AHK2 Δ (the example 11) and p415CYC-AHK3 (the example 8). The transformation was carried out by employing Polyethylene glycol/lithium acetate (PEG/LiAc)-mediated transformation method according to the description of VII. Library

Transformation & Screening Protocols disclosed in MATCHAMAKER Two-Hybrid System 3 User Manual p. 22 from CLONTECH Co.

Transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 were produced by selecting in the DOLU + Gal culture medium based on disappearance of leucine nutrient requirement in the transformed cell.

(Example 13) Response of transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 to cytokinin (Part 1)

A culture solution 10 μ l (about 800 clones of yeast) of the

transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 produced by the example 12 was spotted on DOLU + Gul agar media containing 10 μ M of trans-zeatin and cultured at 30°C for 30 hours. After incubation, the growth state of the transformed cells was observed and photographed by a digital camera.

As a result, any of the transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 showed high growth in the case of using the DOLU + Gul agar culture media containing trans-zeatin as compared with that in the case of using the DOLU + Gul agar culture media containing no trans-zeatin. The results showed that the transformed cells responded to cytokinin and that they were possible to be grown in the DOLU + Gul agar culture media. Further the transformed cells were found possible to be grown in the DOLU + Gal agar culture media independently of the existence trans-zeatin.
(Example 14) Response of transformed cells TM182-CRE1, TM182-AHK2 Δ and TM182-AHK2 to cytokinin (Part 2)

Culture solutions of the transformed cells TM182-CRE1, TM182-AHK2 Δ and TM182-AHK2 produced by the example 12 were spotted on DOLU + Gul agar media containing cytokinin in a variety of concentrations (1 nM, 10 nM, 100 nM, 1 μ M, 10 μ M, 100 μ M) and cultured at 30°C for 30 hours. After incubation, the growth state of the transformed cells was observed and photographed by a digital camera. The lowest supply concentrations of trans-zeatin and cis-zeatin in which the respective transformed cells could be grown were shown in Table 1.

Table 1

cytokinin	TM182-CRE1	TM182-AHK2	TM182-AHK2Δ
trans-zeatin	10 μ M	1 μ M	100nM
cis-zeatin	no growth	10 μ M	1 μ M

(Example 15) Method for searching substance having agonist-activity to cytokinin receptor (Part 1)

The transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2Δ and TM182-AHK3 produced in the example 12 were inoculated in 200 ml of DOLU + Gal culture media and pre-cultured at 30°C for 36 hours. The pre-cultured solutions were diluted with DOLU + Gul media as to become 0.100 as the optical density (OD₆₀₀) and further the resultants were diluted with DOLU + Gul media at a dilution rate of 1/200 to obtain diluted pre-cultured solutions.

An assay plate was prepared by filling respective wells of a 96-well plate with 20 μ l of solutions which were prepared by diluting DMSO solution (10mM) of each examinee substance with DOLU + Gul medium at a dilution rate of 1/100, said solutions containing each examinee substance to be 100 μ M at the final concentration. Simultaneously, an assay plate only filled with 20 μ l of solutions which were prepared by diluting DMSO solution with DOLU + Gul medium, said solutions containing no examinee substance, was prepared as the blank sections.

The diluted pre-cultured solutions were added in 200 μ l each into the respective wells of both assay plates and cultured at 30°C for 24 hours and then the optical density (OD₆₂₀) of each well was measured by a plate reader. The agonist-activity of the examinee substances to the cytokinin

receptor was detected by comparing the optical density measured in the testing sections to which the examinee substances were added with the optical density measured in the blank sections. The optical density of the culture solutions of the transformed cells in the testing sections to which the examinee substances were added were shown in Table 2. Compound B showing the higher optical density measured in the testing sections to which the examinee substances were added than that in the blank sections were selected as agonist-active substance to the cytokinin receptor.

Table 2

Examinee substance	TM182-AHK 2	TM182-AHK 2Δ	TM182-AHK 3
DMSO	0.01	0	0.51
Compound A ^{*1}	0.01	0	0.54
Compound B ^{*2}	0.45	0.89	0.88

*¹ Abscisic acid (=negative control)

*² 6-Benzyl aminopurine (=positive control)

(Example 16) Method for searching substance having antagonist-activity to cytokinin receptor (Part 2)

The transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2Δ and TM182-AHK3 produced in the example 12 are inoculated in 200 ml of DOLU + Gal culture media and cultured at 30°C for 30 hours to obtain pre-cultured solutions.

An assay plate is prepared by filling respective wells of a 96-well plate with 200 μ l of each DOLU + Gul medium mixed with 1 μ M of trans-zeatin (cytokinin), and into the assay plate is put each examinee substance to be 1 μ M at the final concentration. Simultaneously, an assay plate only filled with 200 μ l of the DOLU + Gal medium mixed with 1 μ M of trans-zeatin is prepared as the blank sections

The pre-cultured solutions are added in 20 μ l each into the respective wells of both assay plates and cultured at 30°C for 30 hours and then the optical density of each well is measured by a plate reader. The antagonist-activity of the examinee substances to the cytokinin receptor is detected by comparing the optical density measured in the testing section to which the examinee substances are added with the optical density measured in the blank sections. The examinee substances showing the lower optical density measured in the testing sections to which the examinee substances are added than that in the blank sections are selected as antagonist-active substance to the cytokinin receptor.

(Example 17) Method for searching substance having agonist-activity to cytokinin receptor (Part 3)

The transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 produced in the example 12 are inoculated in 200 ml of DOLU + Gal culture media and cultured at 30°C for 30 hours to obtain pre-cultured solutions.

The pre-cultured transformed cells (TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3) are spot-added in 10 μ l to the respective DOLU + Gul agar culture media to which agonist-active

substances to the cytokinin receptor selected by the example 15 are added while their concentration being changed from 10 nM to 100 μ M and then is cultured at 30°C for 30 hours. After incubation, the intensity of the agonist-activity of the examinee substances to the cytokinin receptor is detected and confirmed based on the lowest concentration at which transformed cells (TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3) are observed to grow.

(Example 18) Method for searching substance having antagonist-activity to cytokinin receptor (Part 4)

The transformed cells TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3 produced in the example 12 are inoculated in 200 ml of DOLU + Gal culture media and cultured at 30°C for 30 hours to obtain pre-cultured solutions.

The pre-cultured transformed cells (TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3) are spot-added in 10 μ l to the respective DOLU + Gul agar culture media to which antagonist-active substances to the cytokinin receptor selected by the example 16 are added while their concentration being changed from 10 nM to 100 μ M and also 10 μ M of trans-zeatin (cytokinin) is added and then is cultured at 30°C for 30 hours. After incubation, the intensity of the antagonist-activity of the examinee substances to the cytokinin receptor is detected and confirmed based on the lowest concentration at which transformed cells (TM182-CRE1, TM182-AHK2, TM182-AHK2 Δ and TM182-AHK3) are not observed to grow.

Hereinafter, the medium compositions to be used in the present invention will be described:

(a) DOLU + GLU culture medium

Bacto-yeast nitrogen base without amino acids	6.7g
Glucose	20g
Drop-out mix (x)	2.0g
Distilled water	1000ml

(b)DOLU + GAL culture medium

Bacto-yeast nitrogen base without amino acids	6.7g
Glucose	20g
Drop-out mix (x)	2.0g
Distilled water	1000ml

(x) Drop-out mix: Drop-out mix is a combination of the following ingredients.

Adenine	0.5g	Lysine	2.0g
Alanine	2.0g	Methionine	2.0g
Arginine	2.0g	para-Aminobenzoic acid	0.2g
Asparagine	2.0g	Phenylalanine	2.0g
Aspartic acid	2.0g	Proline	2.0g
Cysteine	2.0g	Serine	2.0g
Glutamine	2.0g	Threonine	2.0g
Glutamic acid	2.0g	Tryptophan	2.0g
Glycine	2.0g	Tyrosine	2.0g
Histidine	2.0g	Valine	2.0g
Inositol	2.0g	Isoleucine	2.0g

(c) DOLU + GLU agar culture medium

A solid culture medium prepared by adding 2% (W/V) of agar into the culture medium (a)

(d) DOLU + GAL agar culture medium

A solid culture medium prepared by adding 2% (W/V) of agar into the culture medium (c)

" Sequence table free text"

SEQ ID No: 9

Oligonucleotide primer designed for PCR

SEQ ID No: 10

Oligonucleotide primer designed for PCR

SEQ ID No: 11

Oligonucleotide primer designed for PCR

SEQ ID No: 12

Oligonucleotide primer designed for PCR

SEQ ID No: 13

Oligonucleotide primer designed for PCR

SEQ ID No: 14

Oligonucleotide primer designed for PCR

SEQ ID No: 15

Oligonucleotide primer designed for PCR

SEQ ID No: 16

Oligonucleotide primer designed for PCR

SEQ ID No: 17

Oligonucleotide primer designed for PCR

SEQ ID No: 18

Oligonucleotide primer designed for PCR

SEQ ID No: 19

Oligonucleotide primer designed for PCR

SEQ ID No: 20

Oligonucleotide primer designed for PCR

SEQ ID No: 21

Oligonucleotide primer designed for PCR

SEQ ID No: 22

Oligonucleotide primer designed for PCR